drugset / Trial / NCT07480824
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with hepatic impairment after a single dose, and to evaluate the safety of the drug in these patients after a single dose.
Timeline
- Start
- 2026-04-01
- Primary completion
- 2026-10
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TQ05105 | Small molecule | 10 mg | Oral |
| Comparator | TQ05105 | Small molecule | 15 mg | Oral |